Advertisements



We are Sorry, This Page doesn't Exist


Global Blood Therapeutics is gambling on its sickle cell drug — and investors aren’t happy

The results, which were mostly positive, should have pleased investors. But the company is betting they are enough to score a drug approval — and is pausing the trial......»»

Category: topSource: marketwatchJun 27th, 2018

Cara Therapeutics Rallies On Positive Opioid Receptor Agonist Trial Results

Cara Therapeutics Inc (NASDAQ: CARA) popped more than 32 percent Wednesday morning after management reported positive top-line data for a drug candidate.  read more.....»»

Category: blogSource: benzingaJun 27th, 2018

Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment

Global Blood Therapeutics Inc. shares dropped as much as 12% in premarket trade on Wednesday after the company reported results for a late-stage trial of sickle cell disease therapy, and said that it met with the U.S. Food and Drug Ad.....»»

Category: topSource: marketwatchJun 27th, 2018

Nektar Plummets Amid Concern Over Cancer-Drug Trial Results

Nektar Therapeutics lost a third of its value in Monday trading after response rates in melanoma and kidney cancer patients decreased in a mid-stage trial of the company’s cancer drug in combination with Bristol-Myers Squibb Co.’s Opdivo......»»

Category: topSource: moneycentralJun 4th, 2018

CRISPR, Vertex say FDA puts brakes on upcoming gene editing trial

Cambridge startup CRISPR Therapeutics and Boston-based Vertex Pharmaceuticals said on Wednesday that the FDA has put on hold a highly anticipated upcoming trial of their experimental gene editing drug for sickle cell disease. CRISPR (Nasdaq: CRIS.....»»

Category: topSource: bizjournalsMay 30th, 2018

Esperion Therapeutics Shares Briefly Halted on Late-Stage Cholesterol Trial

Esperion Therapeutics shares were halted in premarket trading on Wednesday after the firm announced late-stage trial results for its cholesterol drug......»»

Category: blogSource: 247wallstMay 23rd, 2018

Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 22nd, 2018

Nabriva Therapeutics unveils positive results in bacterial pneumonia drug trial

Nabriva Therapeutics PLC on Monday reported positive results in a a late-stage trial of a treatment for bacterial pneumonia, saying the phase 3 trial of Lefamulin Evaluation Against Pneumonia (LE.....»»

Category: topSource: marketwatchMay 21st, 2018

Nabriva Therapeutics announces positive results in late-stage trial of bacterial pneumonia drug

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchMay 21st, 2018

Voyager Therapeutics receives FDA guidance on VY-AADC development path

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall46 min. ago

Start of Pfizer trial encouraging for Spark Therapeutics, says Cantor Fitzgerald

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 0 min. ago

Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful

Magenta Therapeutics Inc (NASDAQ: MGTA), which made an initial public offering last month, is operating in an area largely overlooked by drug developers, acco Latest Ratings for MGTA .....»»

Category: blogSource: benzinga19 hr. 0 min. ago

Why investors injected $62 million into a Peninsula biotech targeting a deadly lung disease

Pliant Therapeutics expects to have 50 employees by the end of the year and is recruiting for its first clinical trial......»»

Category: topSource: bizjournals21 hr. 16 min. ago

Here"s Why Cara Therapeutics Jumped 56.5% in the First Half of 2018

A big clinical trial success gave investors reason to smile......»»

Category: topSource: foxnewsJul 15th, 2018

Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

Shares of the biotech company Advaxis Inc. surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The clinical hol.....»»

Category: topSource: marketwatchJul 13th, 2018

Zogenix stock soars on anti-seizure drug results

Zogenix (ZGNX) stock surged more than 17% Thursday as the company's seizure drug helped to reduce seizures during its latest clinical trial......»»

Category: topSource: moneycentralJul 12th, 2018

Zogenix Stock Soars on Anti-Seizure Drug Results

Zogenix (ZGNX) stock surged more than 17% Thursday as the company's seizure drug helped to reduce seizures during its latest clinical trial......»»

Category: topSource: moneycentralJul 12th, 2018

Benzinga"s Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) read more.....»»

Category: blogSource: benzingaJul 12th, 2018

Disagreements doomed Buckingham"s bid for Scioto Peninsula, city emails show

The deal between the Indianapolis company chosen to spearhead the $500 million Scioto Peninsula redevelopment, the city of Columbus and Columbus Downtown Development Corp. was falling apart long before the June announcement that the project was on hold a.....»»

Category: topSource: bizjournalsJul 11th, 2018

Cara Therapeutics announces dosing of patients in Phase 2 trial of Oral Korsuva

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 11th, 2018